News


December 6, 2016

Roche expands distribution alliance with the life science business of Merck KGaA, Darmstadt, Germany to include Kapa Biosystems qPCR and endpoint PCR Portfolios

Pleasanton, CA, November, 28, 2016 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced an expansion of their distribution alliance with the life science business of Merck KGaA, Darmstadt, Germany, to now include the qPCR and endpoint PCR portfolios1 from Kapa Biosystems. Merck KGaA, Darmstadt, Germany operates as MilliporeSigma in the US and Canada. Kapa Biosystems was previously acquired by Roche in December of 2015.


May 9, 2016

Roche announces direct sales of Kapa Biosystems NGS products in Canada

Increased customer access to Kapa NGS, HiFi kits through Roche Diagnostics Canada


March 22, 2016

Color Genomics Chooses Kapa Biosystems Solution for an Efficient NGS Library Platform

KAPA HyperPlus library construction kits deliver rapid and robust results in high-throughput NGS pipeline


December 8, 2015

Roche finalizes acquisition of Kapa Biosystems to strengthen next-generation sequencing product offerings

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced regulatory clearance to finalize acquisition of Kapa Biosystems, Inc. (Kapa), a privately-held company headquartered in Wilmington, Massachusetts, US. Kapa Biosystems is a provider of genomic tools in the life sciences sector that employs proprietary technologies to optimize enzymes for next-generation sequencing (NGS), as well as polymerase chain reaction (PCR) and real-time PCR applications¹.


October 15, 2015

Kapa Biosystems Earns ISO 13485:2003 Certification

Kapa Biosystems today announced that it has earned ISO 13485:2003 certification for the design, development, and manufacturing of molecular biology kits and reagents for in vitro diagnostic applications. This certification is recognized as the international quality standard for medical devices.


August 19, 2015

Roche to acquire Kapa Biosystems to strengthen next-generation sequencing product offerings

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that it has signed a definitive agreement to acquire Kapa Biosystems, Inc. (Kapa) a privately-held company headquartered in Wilmington, Massachusetts, US. Kapa Biosystems is a provider of genomic tools in the life sciences sector that employs proprietary technologies to optimize enzymes for next-generation sequencing (NGS), as well as polymerase chain reaction (PCR) and real-time PCR applications¹.


July 20, 2015

10X Genomics Selects Kapa Biosystems as a Reagents Supplier for the GemCode™ Platform

10X Genomics and Kapa Biosystems today announced that Kapa’s DNA library preparation reagents have been incorporated into the GemCode Platform, enabling a more streamlined workflow generating high quality sequencing data.


May 18, 2015

Kapa Biosystems Launches New RNA Prep Kit to Maximize Sequencing Efficiency

Ribodepletion kit boosts NGS throughput and data quality for more comprehensive view of transcriptome


March 30, 2015

Kapa Biosystems Launches Inhibitor-Resistant qPCR Reagent Kit to Accelerate Workflows and Improve Target Amplification and Quantification of Crude Samples

KAPA PROBE FORCE qPCR Kit enables direct amplification of challenging samples for genotyping and gene expression applications in clinical research and agricultural testing applications


February 26, 2015

Kapa Biosystems Launches DNA and RNA Sample Preparation Products at 2015 AGBT Meeting

KAPA HyperPlus Kit features integrated DNA fragmentation and 2.5-hour library construction workflow and KAPA Stranded RNA-Seq Kit with RiboErase, the only solution able to remove up to 99.98% of rRNA for comprehensive transcriptome profiling


December 8, 2014

Kapa Biosystems Expands Partnership with Roche NimbleGen to Include RNA Sample Preparation for Targeted Next-Gen Sequencing

Customized version of KAPA Stranded RNA-Seq Kit enhances Roche NimbleGen SeqCap RNA product offering


December 4, 2014

Kapa Biosystems Strengthens European Commercial Operations with Dedicated Service and Support for Customers in the United Kingdom

Company increases regional investment to support continued success, accelerate future growth, and enhance overall customer experience


November 10, 2014

Dartmouth-Hitchcock Selects Kapa Biosystems Reagents to Assess Quantity and Quality of FFPE DNA for Translational Cancer Research Applications

Researchers to present data showcasing KAPA hgDNA Quantification and QC Kit’s ability to accurately predict next-gen sequencing performance, inform sample processing, and minimize unnecessary costs during AMP 2014 Annual Meeting.


August 27, 2014

KAPA Library Prep Kits achieve ultra-low detection limit and broad patient coverage

A team of researchers from Stanford University found the combination of the KAPA Library Preparation Kits and the Roche NimbleGen sequence capture products to be an economical and ultrasensitive method for quantifying and enriching circulating tumor DNA (ctDNA).


August 4, 2014

Kapa Biosystems Strengthens Investment Across Asia Pacific Region

Latest exclusive distribution agreement with Nippon Genetics builds on continued commercial success of Kapa’s genomics product portfolio over the past seven years in the Japanese market.


June 23, 2014

Ambry Genetics Selects Kapa Biosystems Hyper Prep Kit for New ExomeNext and ExomeNext-Rapid Tests

New exome sequencing offerings for neonatal, pediatric and adult-onset diagnosis feature faster turnaround times, reduced pricing and more comprehensive coverage


March 31, 2014

Kapa Selected for Landmark 100K Foodborne Pathogen Genome Project

Kapa Biosystems, Inc., a leading supplier of reagents for the life science market, today announced that its KAPA Library Preparation Kits have been selected for use in the 100K Foodborne Pathogen Genome Project, an innovative collaboration between the U.S. Food and Drug Administration (FDA), the University of California, Davis, Agilent Technologies Inc., and the Centers for Disease Control and Prevention (CDC).


March 4, 2014

Kapa Biosystems Launches Suite of High-Performance DNA and RNA Products

Kapa Biosystems, Inc., a leading supplier of reagents for the life science market, today announced the launch of products that improve performance and workflows for genomic research. The new suite of products enables researchers to apply the latest next-generation sequencing (NGS) technologies more effectively to millions of low quality and challenging samples, such as formalin-fixed paraffin-embedded (FFPE) tissue common in cancer profiling.


January 27, 2014

Kapa Biosystems Strengthens Leadership Team and Doubles Global Facility Investment

Company makes key management hires and relocates corporate and international headquarters to larger locations in Wilmington, Mass. and Cape Town, South Africa.


December 20, 2013

Roche NimbleGen and Kapa Biosystems Team Up to Provide NGS Target Enrichment Workflow Solution

Roche and Kapa Biosystems announced today a partnership to provide an optimized NGS target enrichment workflow solution.